Pricing Log in Create free account

AC Immune (ACIU) vs BridgeBio Oncology Therapeutics, Inc (BBOT)

AC Immune and BridgeBio Oncology Therapeutics, Inc are both Biotechnology companies. AC Immune and BridgeBio Oncology Therapeutics, Inc are of similar size ($249.4M and $236.5M). BridgeBio Oncology Therapeutics, Inc has the higher net margin (0.00% vs −1,783.7%) and the lower return on invested capital (−127.7% vs 0.00%). Across the 11 metrics below, AC Immune leads on 6 and BridgeBio Oncology Therapeutics, Inc on 5.

Valuation

Metric ACIU BBOT Biotechnology median
P/E n/m n/m 8.50
P/S 50.83 n/m 9.71
P/B 5.30 0.70 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 31.31 n/m 9.21
Earnings yield (34.31%) (97.87%) (33.15%)
Free cash flow yield (35.48%) (67.14%) (25.50%)

Profitability

Metric ACIU BBOT Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (1,745.75%) 0.00% 0.00%
Net margin (1,783.66%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (252.10%) (56.36%)
Return on assets 0.00% (96.69%) (48.04%)
Return on invested capital 0.00% (127.66%) 0.00%

Growth

Metric ACIU BBOT Biotechnology median
Revenue growth (TTM) (85.56%) — 6.02%
EPS growth (last fiscal year) (44.83%) 99.93% 30.26%
Revenue growth, 5-year CAGR (47.84%) — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ACIU BBOT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.93 4.69 4.72
Net debt to EBITDA 1.37 2.93 0.96

Dividend

Metric ACIU BBOT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACIU BBOT Biotechnology median
Market cap 249.35m 236.52m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack